IIT Research protocol: Ozurdex® at Moorfields Eye Hospital
Research type
Research Study
Full title
Identifying patient cohorts that are most likely to benefit from Ozurdex® at Moorfields Eye Hospital
IRAS ID
292955
Contact name
Dawn Sim
Contact email
Sponsor organisation
Moorfields Eye Hospital NHS Foundation Trust
Duration of Study in the UK
0 years, 8 months, 4 days
Research summary
Moorfields Eye Hospital NHS Foundation Trust is a world-renowned tertiary referral centre with 32 clinic sites across London. It is the oldest and largest centre for ophthalmic treatment, teaching, and research in Europe and provides excellent care for a diverse population.
Moorfields have pioneered the analysis of large UK clinical datasets using deep-learning algorithms and their established data-processing infrastructure continues to support world-leading discoveries in applied deep-learning.
At Moorfields Eye Hospital we have estimated that more than 7,500 patients
with a diagnosis of Diabetic Macular Oedema (DMO) or Retinal Vein Occlusion (RVO) have required anti - vascular endothelial growth factor (anti-VEGF) injections. Often patients do not respond to the anti-VEGF injections, and
require a second type of treatment which is most often Ozurdex® intravitreal injections.We propose to use this unique repository of ophthalmology data at Moorfields to:
evaluate the treatment outcomes of non-responders that go on to receive Ozurdex® in a real-world clinical setting; identify predictive variables of these outcomes; and find out whether anti-VEGF non-responders can be identified before commenting anti-VEGF therapy.Using both classical modelling techniques and deep-learning algorithms to forecast visual outcomes following Ozurdex® therapy would be helpful in a clinical setting and could be used to identify patient cohorts that are most likely to benefit from Ozurdex® in the future, and help prevent vision loss sooner.
Patients with DMO and RVO requiring anti-VEGF therapy over the past 12 years and meet the following the study inclusion criteria will be eligible. The study will run from January 2021 to August 2021.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
21/NE/0193
Date of REC Opinion
10 Nov 2021
REC opinion
Further Information Favourable Opinion